Business Context and Reporting Period
This summary reflects PerkinElmer, Inc.’s unaudited Form 10-Q for the three months ended April 1, 2012, compared with the three months ended April 3, 2011. The filing identifies PerkinElmer—not Revvity, Inc.—as the registrant. PerkinElmer reported Human Health and Environmental Health segments and had acquired Caliper Life Sciences in November 2011.
Key Financial Metrics
| Metric | Q1 2012 | Prior comparable quarter |
|---|---|---|
| Revenue | $510.9 million | $447.2 million |
| Gross margin | 45.4% | 44.8% |
| Operating income | $36.4 million | $41.4 million |
| Operating margin | 7.1% | 9.3% |
| Continuing-operations net income | $22.1 million | $27.3 million |
| Net income | $22.6 million | $24.9 million |
| Diluted EPS | $0.20 | $0.22 |
| Cash from continuing operations | $15.3 million | $47.3 million |
| Cash and cash equivalents at period end | $144.8 million | $142.3 million at Jan. 1, 2012 |
Revenue increased 14% year over year; the filing attributes approximately 10% growth to acquisitions and approximately 1% decline to unfavorable foreign exchange. Product revenue was $357.2 million and service revenue was $153.7 million. Human Health revenue rose 26% to $254.0 million, while Environmental Health revenue rose 5% to $256.9 million. Segment operating income was $21.9 million in Human Health (up 2%) and $26.4 million in Environmental Health (down 13%).
Gross margin improved 62 basis points, driven by sales volume, product mix, and productivity, partly offset by acquisition costs. Operating margin fell 214 basis points as acquisition-related costs, sales and marketing spending, and R&D investment increased. Interest and other expense rose to $12.8 million from $5.8 million, primarily reflecting higher debt and interest costs following the 2021 notes issuance. The continuing-operations effective tax rate was 6.3%, versus 23.5%, mainly due to favorable permanent tax differences and a greater expected share of profits in lower-tax jurisdictions.
Operating cash flow from continuing operations declined by $32.0 million year over year. Management cited working-capital use, including increased inventory, lower accounts payable, and timing of tax, restructuring, salary, and benefit payments. Capital expenditures were $5.2 million. Current assets were $908.1 million and current liabilities were $602.8 million. Long-term debt was $934.0 million; the company had $287.0 million drawn on its $700.0 million revolving facility and approximately $400.0 million available for additional borrowing, net of letters of credit.
Material Changes, Outlook, Risks, and Unusual Items
- The Caliper acquisition contributed to growth and increased acquisition-related amortization and costs. The purchase-price allocation remained preliminary. Acquisition accounting adjustments reduced reported Q1 2012 revenue by $6.5 million compared with revenue the acquired businesses otherwise would have recorded.
- Restructuring and contract termination charges were $6.2 million, including a Q1 plan to realign operations and production resources that reduced headcount by 129 employees.
- Management described demand as favorable across screening, medical imaging, research, laboratory services, environmental testing, food and consumer safety, and industrial applications. It expected stable spending trends and continued growth in relevant markets, but provided no specific quantitative earnings or revenue guidance.
- Management expected internal operations to fund operating expenses, capital spending, smaller acquisitions, interest, and dividends; larger acquisitions and certain long-term obligations could require external financing. The company stated it was in compliance with applicable debt covenants.
- The company planned to repatriate about $350 million of previously unremitted foreign earnings by the end of fiscal 2014; $161.3 million had been repatriated by April 1, 2012. A $79.7 million tax provision related to the plan had been recorded in fiscal 2011.
- Key risks include economic and customer-funding weakness, foreign-exchange exposure (about 62% of business conducted outside the U.S.), acquisition integration and goodwill/intangible-asset impairment, debt and variable-rate exposure, regulatory and product-liability risks, and dependence on key suppliers and personnel.
- Contingencies include a $6.8 million environmental accrual and the stayed Enzo patent and commercial dispute. Management did not expect these matters to have a material adverse effect, while acknowledging uncertainty. The filing also disclosed $49.3 million of gross tax-effected unrecognized tax benefits.
Important Facts for Investors to Verify
- Confirm the intended issuer: the supplied filing is PerkinElmer’s 2012 10-Q, not a filing under the name Revvity, Inc.
- Assess how much of reported revenue growth came from Caliper and other acquisitions, and the effect of deferred-revenue purchase accounting.
- Track whether margin pressure and lower operating cash flow persist as integration costs, R&D and sales investment, and working-capital needs evolve.
- Review debt levels, revolver availability, interest-rate sensitivity, covenant headroom, and the planned foreign-earnings repatriation.
- Monitor restructuring execution and payments, the preliminary Caliper purchase-price allocation, tax examinations, and legal and environmental contingencies.